151 related articles for article (PubMed ID: 7273032)
1. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
Karakousis CP; Didolkar MS; Han T
Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
[No Abstract] [Full Text] [Related]
2. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
3. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
5. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
Halpern J; Catane R; Biran S; Fuks Z
Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
[No Abstract] [Full Text] [Related]
6. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
[No Abstract] [Full Text] [Related]
7. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
[TBL] [Abstract][Full Text] [Related]
8. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
Robidoux A; Gutterman JU; Bodey GP; Hersh EM
Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
Yadeau R; Bates HA; Fortuny I
Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
[No Abstract] [Full Text] [Related]
10. Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Gough IR; Bolton PM; Clunie GJ; Burnett W
Aust N Z J Surg; 1978 Jun; 48(3):296-300. PubMed ID: 281221
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.
Leahy BC; Honeybourne D; Brear SG; Carroll KB; Thatcher N; Stretton TB
Eur J Respir Dis; 1985 Jan; 66(1):50-4. PubMed ID: 3979476
[TBL] [Abstract][Full Text] [Related]
12. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
Jacquillat C; Banzet P; Civatte J; Puissant A; Cottenot F; Israel L; Belaich S; Chastang C; Maral J
Recent Results Cancer Res; 1978; 68():346-58. PubMed ID: 111323
[No Abstract] [Full Text] [Related]
14. [Treatment of neoplastic pleural effusion by intrapleural administration of Corynebacterium parvum vaccine].
Krasucka-Kluźniak A; Krakówka P
Pneumonol Pol; 1985 May; 53(5):240-7. PubMed ID: 4047949
[No Abstract] [Full Text] [Related]
15. Phase I study of corynebacterium parvum in patients with solid tumors.
Band PR; Jao-King C; Urtasun RC; Haraphongse M
Cancer Chemother Rep; 1975; 59(6):1139-45. PubMed ID: 769953
[TBL] [Abstract][Full Text] [Related]
16. Immunological response in patients receiving Corynebacterium parvum therapy.
Osborn DE; Castro JE
Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
[No Abstract] [Full Text] [Related]
17. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
[TBL] [Abstract][Full Text] [Related]
18. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
20. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.
Webb HE; Oaten SW; Pike CP
Br Med J; 1978 Feb; 1(6109):338-40. PubMed ID: 623981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]